Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain.

Tytuł:
Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain.
Autorzy:
José Manuel Sousa
Mercedes Vergara
Federico Pulido
Gloria Sánchez Antolín
Lander Hijona
Fernando Carnicer
Diego Rincón
Javier Salmerón
Beatriz Mateos-Muñoz
Antoni Jou
Benjamín Polo-Lorduy
Ángel Rubín
Ana Escarda
Patricia Aguilar
Teresa Aldámiz-Echevarría
Luisa García-Buey
José A Carrión
Manuel Hernández-Guerra
Sonia Chimeno-Hernández
Nuria Espinosa
Rosa Mª Morillas
Raúl J Andrade
Manuel Delgado
Adolfo Gallego
Marta Magaz
José María Moreno-Planas
Ángel Estébanez
Mikel Rico
Fernando Menéndez
Blanca Sampedro
Luís Morano
Sonia Izquierdo
José Manuel Zozaya
Manuel Rodríguez
Senador Morán-Sánchez
Sara Lorente
Ignacio Martín-Granizo
Miguel Ángel Von-Wichmann
Marcial Delgado
Amanda Manzanares
Temat:
Medicine
Science
Źródło:
PLoS ONE, Vol 14, Iss 11, p e0225061 (2019)
Wydawca:
Public Library of Science (PLoS), 2019.
Rok publikacji:
2019
Kolekcja:
LCC:Medicine
LCC:Science
Typ dokumentu:
article
Opis pliku:
electronic resource
Język:
English
ISSN:
1932-6203
Relacje:
https://doaj.org/toc/1932-6203
DOI:
10.1371/journal.pone.0225061
Dostęp URL:
https://doaj.org/article/7dbb76fef2474e14bc130178fddbd4a1  Link otwiera się w nowym oknie
Numer akcesji:
edsdoj.7dbb76fef2474e14bc130178fddbd4a1
Czasopismo naukowe
AimWe describe the effectiveness and safety of the interferon-free regimen ombitasvir/paritaprevir/ritonavir plus dasabuvir with or without ribavirin (OBV/PTV/r ± DSV ± RBV) in a nationwide representative sample of the hepatitis C virus (HCV) monoinfected and human immunodeficiency virus-1/hepatitis C virus (HIV/HCV) coinfected population in Spain.Material and methodsData were collected from patients infected with HCV genotypes 1 or 4, with or without HIV-1 coinfection, treated with OBV/PTV/r ± DSV ± RBV at 61 Spanish sites within the initial implementation year of the first government-driven "National HCV plan." Effectiveness was assessed by sustained virologic response at post-treatment week 12 (SVR12) and compared between monoinfected and coinfected patients using a non-inferiority margin of 5% and a 90% confidence interval (CI). Sociodemographic and clinical characteristics or patients and adverse events (AEs) were also recorded.ResultsOverall, 2,408 patients were included in the intention-to-treat analysis: 386 (16%) were patients with HIV/HCV. Patient selection reflected the real distribution of patients treated in each participating region in Spain. From the total population, 96.6% (95% CI, 95.8-97.3%) achieved SVR12. Noninferiority of SVR12 in coinfected patients was met, with a difference between monoinfected and coinfected patients of -2.2% (90% CI, -4.5% - 0.2%). Only genotype 4 was associated with non-response to OBV/PTV/r ± DSV ± RBV treatment (pConclusionsOur results confirm that OBV/PTV/r ± DSV ± RBV is effective and generally well tolerated in a representative sample of the HCV monoinfected and HCV/HIV coinfected population in Spain within the experience of a national strategic plan to tackle HCV.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies